Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Chemomab Therapeutics Ltd DRC (CMMB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Chemomab Therapeutics DRC's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.8410 -0.0290    -3.33%
17/05 - Closed. Currency in USD ( Disclaimer )
After Hours
0.8200
-0.0210
-2.4970%
23:04:18 - Real-time Data
  • Volume: 54,633
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.8265 - 0.8800
Type:  Equity
Market:  United States
Chemomab Therapeutics DRC 0.8410 -0.0290 -3.33%

Chemomab Therapeutics DRC Company Profile

 
Read the Chemomab Therapeutics Ltd DRC company profile to learn more about the business and the management team. View Chemomab Therapeutics Ltd DRC facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Contact Information

Address Building 7 Kiryat Atidim
Tel Aviv, 6158002
Israel
Phone 972 77 331 0156
Fax -

Top Executives

Name Age Since Title
Neil Harris Cohen 58 2020 Independent Director
Alan Charles Moses 74 2021 Independent Director
Arun J. Sanyal - - Member of Scientific Advisory Board
Nissim Darvish 59 2021 Independent Chairman
Massimo Pinzani - - Member of Scientific Advisory Board
Claude Nicaise 70 2021 Independent Director
Adi Mor George 41 2011 Co-Founder, Chief Scientific Officer, CEO & Executive Director
Scott L. Friedman - - Member of Scientific Advisory Board
Jill M. Quigley 47 2022 Independent Director
Jacob George - - Member of Scientific Advisory Board
Dinesh Khanna - - Member of Scientific Advisory Board
Francesco Del Galdo - - Member of Scientific Advisory Board
Marco Matucci-Cerinic - - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CMMB Price Commentary

Write your thoughts about Chemomab Therapeutics Ltd DRC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email